PRTC Affiliates Granted Key Digital Medicine IP
10 April 2018
PureTech Health plc
PureTech Health Affiliates Expand Digital Medicine IP Portfolios with Key Patent Issuances
US and international patent grants for Akili and Sonde technology platforms highlight PureTech's foundational leadership position in the growing field of digital medicine
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced, clinical-stage biopharmaceutical company, announced today that its affiliates, Akili Interactive Labs, Inc. and Sonde Health, Inc., have been granted key patents broadly covering their respective proprietary technology platforms. Akili, which is pioneering the development of digital treatments for cognitive dysfunction, has been granted three patents in the US and Japan. Sonde, which is developing an innovative vocal biomarker technology for monitoring, managing, and diagnosing mental and physical medical conditions from seconds of speech, has been granted patents in the US and Australia.
"As a part of PureTech's mission, we are developing new categories of medicine to improve the lives of patients," said Eric Elenko, Chief Research and Strategy Officer at PureTech Health. "These patents recognise the strength of our leadership, innovation, and IP position in digital medicine and also validate our novel approaches to diagnosing and treating serious and devastating medical conditions."
Akili's newest patents issued by the United States Patent and Trademark Office (USPTO), No. 9,940,844, and Japan Patent Office (JPO), Nos. 6177131 and 6297096, broadly cover the unique mechanism of presenting a range of specific stimuli that engage targeted neural networks in the prefrontal cortex, the area of the brain known to play a key role in cognitive control, to assess and improve cognitive abilities. The patents are part of an expanding and comprehensive portfolio of patent applications and other intellectual property covering Akili's technology platform, and they will provide protection in the US and Japan until 2032 and 2031, respectively.
In 2017, Akili announced positive results from its randomised, controlled pivotal study of AKL-T01, the company's flagship product designed to treat paediatric ADHD. Akili plans to file AKL-T01 with the US Food and Drug Administration (FDA) for clearance in the first half of 2018. If approved, AKL-T01 would represent the first digital medicine to be cleared by FDA to directly treat an underlying disease.
Sonde's newest patents issued by the USPTO and Intellectual Property Australia (IP Australia) broadly cover methods to detect physical and psychological conditions through the company's vocal biomarker technology. US Patent No. 9,936914, provides protection through 2032 and is specifically focused on extracting proprietary acoustic features from targeted segments of speech to measure and detect vocal biomarkers for physical or psychological conditions. Patent No. 2014374349, issued by IP Australia, broadly covers the use of vocal biomarker technology to detect a host of physical or psychological conditions in the human body and will provide protection until 2034. Both patents are exclusively licensed by Sonde from the Massachusetts Institute of Technology.
Sonde's proprietary voice-based technology has been tested in over 3,000 subjects for the detection of neuropsychological conditions, such as depressive disorders, Parkinson's disease, Alzheimer's disease and multiple sclerosis. Sonde's platform is designed to enable voice-interactive devices, including smartphones, to detect and quantify a rapidly growing number of health-related features through subtle characteristic changes in the voice. Sonde has the potential to fundamentally change the way mental and physical health is monitored, managed and diagnosed.
Akili and Sonde have broad and growing IP portfolios now including more than 80 issued and pending patents and patent applications broadly covering digital medicine technology platforms for the treatment and assessment of cognitive dysfunction and physical and psychological conditions, respectively.
About PureTech Health
PureTech Health (PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the "BIG" axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, PureTech Health is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programmes, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech's research and development pipeline has been advanced in collaboration with some of the world's leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to PureTech's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither PureTech Health nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
|
Investors |
EU media |
US media |
|
Allison Mead Talbot +1 617 651 3156 amt@puretechhealth.com |
Ben Atwell, Rob Winder +44 (0) 20 3727 1000 ben.atwell@FTIconsulting.com |
Tom Donovan +1 857 559 3397 tom@tenbridgecommunications.com |
This information is provided by RNS
Latest directors dealings
- 2 days ago Savannah Energy
- 2 days ago Buccaneer Energy PLC
- 2 days ago Savannah Energy
- 2 days ago Carclo
- 2 days ago Schroder Japan Growth Fund